The global summit series where the people who generate real-world evidence meet the regulators, HTA bodies, payers and data innovators who decide on it.
Society congresses are built for volume. Vendor conferences are built for pipeline. RWE Connect is built for the moment a regulator, an HTA body or a payer says yes: the evidence that got them there, and the people who produced it.
Every edition is programmed around four pillars. Together they cover the full journey of real-world evidence, from data infrastructure to reimbursement.
What regulators, HTA bodies and payers actually accept, and why.
Turning evidence into reimbursement, pricing and market access outcomes.
The data, methods and machines behind next-generation evidence.
Evidence generated across functions and borders, not in silos.
Each edition carries the same format and standards; what changes is the city and the regulators, payers and leaders on stage.
Transforming Evidence Into Market Access and Healthcare Value, with the MHRA and ABPI on stage alongside global HEOR and access leads.
Evidence Evolution: RWE as the Foundation of Access, Value and Analytics, from tokenization in practice to RWE as an investor value driver.
Drag the globe or select a region. Each pin is an edition; the pulsing marker is where the series is heading next.
No parallel streams. The epidemiologist, the HEOR lead, the market access director and the regulator hear the same session and continue it at the break.
Agencies and policy bodies are programmed as speakers, not name-checked in abstracts. Their expectations frame the discussion.
Around 25 sessions per edition, each chosen because it matters to the whole audience rather than a sub-group.
Sponsors join the conversation with main-stage sessions, but the agenda is set by the organizer, not by a product roadmap.
Every session is framed by the decision it informs: what gets a payer to yes, when linked data reduces uncertainty for HTA, how an investor prices an evidence strategy.
Speakers, sponsors and delegates carry across editions. What starts in Boston continues in London.
The delegate profile across the series, and the roles the programme is written for.
A selection of the regulators, policy leads and global evidence heads who have spoken or are confirmed to speak.
The single track meant I heard the regulator, the payer-facing lead and the data scientist on the same morning. That never happens at a large congress.
We chose our one-to-one meetings from the delegate list ten days out and walked in with a full diary. Every conversation was with a decision-maker.
A room where the questions come from people who will actually use the answer. The panel discussion continued through the drinks reception.
The single track meant I heard the regulator, the payer-facing lead and the data scientist on the same morning. That never happens at a large congress.
We chose our one-to-one meetings from the delegate list ten days out and walked in with a full diary. Every conversation was with a decision-maker.
A room where the questions come from people who will actually use the answer. The panel discussion continued through the drinks reception.
The single track meant I heard the regulator, the payer-facing lead and the data scientist on the same morning. That never happens at a large congress.
We chose our one-to-one meetings from the delegate list ten days out and walked in with a full diary. Every conversation was with a decision-maker.
A room where the questions come from people who will actually use the answer. The panel discussion continued through the drinks reception.
The single track meant I heard the regulator, the payer-facing lead and the data scientist on the same morning. That never happens at a large congress.
We chose our one-to-one meetings from the delegate list ten days out and walked in with a full diary. Every conversation was with a decision-maker.
A room where the questions come from people who will actually use the answer. The panel discussion continued through the drinks reception.
Sponsorship is built around access rather than banners: a pre-qualified senior audience, a place on the main stage, and meetings booked before you arrive.
Speaking slots inside the single-track programme, so every delegate hears you.
Ten days before the event you pick who you want to meet; we schedule it.
Website, brochure, email campaigns, on-site signage and the post-event report.
The Boston 2026 post-show report is the fastest way to judge whether RWE Connect is right for your team or your brand: who came, what was discussed, and what sponsors got out of it.
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Real-world evidence has moved from a supporting role to a strategic imperative. Regulators are expanding its use in submissions. Payers are demanding it for reimbursement. HTA bodies are building it into evaluation frameworks. For pharma, biotech, and data science professionals, the question is no longer whether RWE matters. It is where to go to stay ahead of how it is being applied.
The relationship between real-world evidence, health economics, and market access has tightened. Payers want outcomes data. HTA bodies are embedding RWE into joint assessments. Regulators are expanding guidance on what counts as credible real-world data. For pharma professionals working across these functions, staying current is no longer enough, the work requires active engagement with how standards, methods, and policy expectations are shifting in real time.
Anything else, get in touch and we will reply within two working days.
Yes, for qualifying RWE, HEOR and market access professionals at pharmaceutical and biotechnology companies. Passes are limited, one per company, and approved at the organizer's discretion.
The full two-day programme, all networking sessions, lunches and refreshments, the Day 1 drinks reception, and the delegate networking list.
Yes, for three or more delegates from the same company. Contact us with the number of places you need.
Use the contact form with "Speaking" as the subject and tell us the topic, the format and the edition you have in mind. The programme team reviews proposals on a rolling basis.
Yes. Multi-edition packages are available; request the prospectus and note the editions you are interested in.
An Asia Pacific edition is under consideration. If you would like to see the series in your region, tell us through the contact form.
Registration is open. The first half of the agenda is published and the full programme is available on request.